网络局限期 网络释义 1. 局限期 ...员一项重要的安全性资讯,针对小细胞肺癌(SCLC)局限期(limited-stage)病患近期进行的研究中发现气管食道廔管生成的危险。 www.taiwan-pharma.org.tw|基于2个网页 释义: 全部,局限期
For limited-stage small cell lung cancer (SCLC), the standard therapy involves platinum-based chemotherapy (usually cisplatin) with etoposide and concurrent radiation. The ADRIATIC trial found that adding durvalumab to this regimen significantly improved outcomes, with a median overall survival of 56 mo...
Limited-stage (LS) small-cell lung cancer (SCLC) remains a therapeutic challenge to medical and radiation oncologists. The treatment of LS-SCLC has evolved significantly over the last two decades with combined-modality therapy now the standard of care. The addition of thoracic radiotherapy (TRT)...
Limited-stage (LS) small-cell lung cancer (SCLC) is defined as disease confined to a tolerable radiation portal without extrathoracic metastases. Despite clinical research over two decades, the prognosis of LS-SCLC patients remains poor. The current standard of care for LS-SCLC patients is ...
Limited (LTD) Stage Small Cell Lung Cancer (SCLC) treated with concurrent BID chest radiotherapy (RT) and etoposide cisplatin (VP/PT) followed by chemotherapy (CT) selected by in vitro Drug Sensitivity Testing (DST)doi:10.1016/0169-5002(91)91917-Z...
LBA81 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial doi:10.1016/j.annonc.2024.08.2324Annals of OncologyS. SenanD.R. SpigelB.C. ChoK. ...
To evaluate the impact of prophylactic cranial irradiation (PCI) on the prognosis of patients with limited-stage small cell lung cancer (SCLC) in the era of MRI surveillance. Limited-stage SCLC patients with complete remission (CR) or partial remission (
The present study explored the risk factors associated with radiotherapy in seniors diagnosed with limited-stage small cell lung cancer (LS-SCLC) to construct and validate a prognostic nomogram. The study retrospectively included 137 elderly patients with LS-SCLC who previously received radiotherapy. Uni...
PURPOSE: A retrospective study was conducted comparing single daily fraction (SDF) thoracic radiotherapy (TRT) with twice daily (BID) TRT to determine the potential benefit of BID TRT in limited-stage small cell lung cancer (SCLC). Endpoints of the study were response, survival, pattern of fail...
Chemotherapy remains the mainstay of treatment for small cell lung cancer (SCLC). For patients with limited-stage disease, the addition of thoracic radiotherapy confers a moderate improvement in local control and a modest survival benefit, but these improvements come at the cost of increased toxic ...